Literatur
-
1
Arentz T, Blum J, von Rosenthal J, Peters K, Kalusche D.
Fokales
paroxysmales Vorhofflimmern. Erste Erfahrungen mit der Behandlung
mit Hochfrequenz-Katheterablation.
Dtsch med Wochenschr.
2000;
125
479-483
-
2
Coplen S E, Antman E M, Berlin J A. et al .
Efficacy and safety of quinidine therapy
for maintenance of sinus rhythm after cardioversion. A meta-analysis
of randomized control trials.
Circulation.
1990;
82
1106-1116
-
3
Danias P G, Caulfield T A, Weigner M J, Silverman D J, Manning W J.
Likelihood
of spontaneous conversion of atrial fibrillation to sinus rhythm.
J
Am Coll Cardiol.
1998;
31
588-592
-
4
European Atrial Fibrillation
Trial Study Group .
Secondary prevention in non-rheumatic
atrial fibrillation after transient ischemic attack or minor stroke.
Lancet.
1993;
342
1255-1262
-
5
Ewy G A.
Optimal
technique for electrical cardioversion of atrial fibrillation.
Circulation.
1992;
86
1645-1647
-
6
Ezekowitz M D, Bridgers S L, James K E. et al .
Warfarin in the prevention of stroke associated
with nonrheumatic atrial fibrillation.
N Engl J Med.
1992;
327
1406-1412
-
7
Fuster V, Rydén L E, Asinger R W. et al .
ACC/AHA/ESC guidelines
for the management of patients with atrial fibrillation.
Eur
Heart J.
2001;
22
1852-1923
-
8
Golzari H, Cebul R D, Bahler R C.
Atrial
fibrillation: restoration and maintenance of sinus rhythm and indications
for anticoagulation therapy.
Ann Intern Med.
1996;
125
311-323
-
9
Hemmer W, Starck C, Botha C. et al .
Initial experience with a modified left
atrial maze procedure concomitant to cardiac surgery.
Herzschr
Elektrophys.
2000;
11
235-243
-
10
Hohnloser S H, Kuck K H, Lilienthal J.
Rhythm
or rate control in atrial fibrillation.
Lancet.
2000;
356
1789-1794
-
11
Kannel W B, Abbott R D, Savage D D, McNamara P M.
Epidemiologic features
of chronic atrial fibrillation.
N Engl J Med.
1982;
306
1018-1022
-
12
Klein A L, Grimm R A, Murray R D. et al .
Use of transesophageal echocardiography
to guide cardoversion in patients with atrial fibrillation.
N
Engl J Med.
2001;
344
1411-1420
-
13
Ozcan C, Jahangir A, Friedman P A. et al .
Long-term survival after ablation of the
atrioventricular node and implantation of a permanent pacemaker
in patients with atrial fibrillation.
N Engl J Med.
2001;
344
1043-1050
-
14
Petersen P, Boysen G, Godtfredsen J. et al .
Plazebo-controlled, randomised trial of
warfarin and aspirin for prevention of thromboembolic complications
in chronic atrial fibrillation.
Lancet.
1989;
1
175-179
-
15
Reisinger J, Gatterer E, Heinze G. et al .
Prospective comparison of flecainide versus
sotalol for immediate cardioversion of atrial fibrillation.
Am
J Cardiol.
1998;
81
1450-1454
-
16
Roy D, Talajic M, Dorian P. et al .
Amiodarone
to prevent recurrence of atrial fibrillation. Canadian Trial of
Atrial Fibrillation Investigators.
N Engl J Med.
2000;
342
913-920
-
17
Schumacher B, Jung W, Lewalter T, Vahlhaus C, Wolpert C, Lüderitz B.
Radiofrequency
ablation of atrial flutter due to administration of class IC antiarrhythmic
drugs for atrial fibrillation.
Am J Cardiol.
1999;
83
710-713
-
18
Shah D, Haissaguerre M, Jais P. et al .
Curative catheter ablation of paroxysmal
atrial fibrillation in 200 patients.
PACE.
2001;
24
1541-1558
-
19
Stroke Prevention in Atrial
Fibrillation Investigators .
Stroke Prevention in Atrial
Fibrillation Study; final results.
Circulation.
1991;
84
527-539
-
20
Stroke Prevention in Atrial
Fibrillation Investigators .
Warfarin versus aspirin
for prevention of thromboembolism in atrial fibrillation study.
Stroke Prevention in Atrial Fibrillation II Study.
Lancet.
1994;
343
687-691
-
21
The Boston Area Anticoagulation
Trial for Atrial Fibrillation Investigators .
The effect
of low-dose warfarin on the risk of stroke in patients with non-
rheumatic atrial fibrillation.
N Engl J Med.
1990;
323
1505-1511
-
22
The NHLNI AFFIRM Investigators .
Atrial
fibrillation follow-up investigation of rhythm management.
Am
J Cardiol.
1997;
79
1198-1202
-
23
Van Gelder I C, Crijns H J, Tieleman R G. et al .
Chronic atrial fibrillation. Success of
serial cardioversion therapy and safety of oral anticoagulation.
Arch
Intern Med.
1996;
156
2585-2592
Korrespondenz
Priv.-Doz. Dr. med. Jens Jung
Medizinische Universitätsklinik und Poliklinik, Innere
Medizin III (Kardiologie/Angiologie), Universitätskliniken
des Saarlandes
66421 Homburg/Saar
Telefon: 06841/1623359
Fax: 06841/1623394
eMail: jung@med-in.uni-saarland.de
